Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03590457 · ClinicalTrials.gov registry record · NA

The Impact of High-Flow Nasal Cannula on Swallow Function

A NA study, sponsored by Rush University Medical Center.

Completed
Registry status
NA
Development phase
18
Enrollment target

NCT03590457 is a NA study that has completed, run by Rush University Medical Center. The registered enrollment target is 18 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03590457, a NA study, has completed, sponsored by Rush University Medical Center.

COMPLETED
Registry status
NA
Development phase
18 participants
Enrollment target

Study Summary

Background: High-flow nasal cannula (HFNC) is a non-invasive heated and humidified oxygen delivery device that is capable of delivering high-flow rates. It is a relatively new modality that has been introduced as an alternative to conventional oxygen therapy. The clinical value of the use of HFNC is not limited to its ventilation and oxygenation effects, it enables the patient to talk and is purported to permit oral feeding during oxygen therapy despite the limited evidence regarding its impact on swallow function. This study will determine the impact of different flow rates of a high-flow nasal cannula on spontaneous swallowing frequency at rest and swallowing effort and timing while swallowing. Methods: This is a prospective study designed to measure swallowing frequency and swallowing effort in fifty healthy adult volunteers. Participants will receive three levels of HFNC flow rates (30, 45, and 60 L/min) through nasal prongs. The study participants will be asked to swallow measured amounts of water and applesauce and subjected to each flow rate for 15 minutes. Swallowing effort measurement through surface electromyography (sEMG) will be recorded at baseline and the three levels of HFNC flow rates interventions.

Interventions

  • DEVICE Airvo 2; High-Flow nasal cannula system

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2018-06-22
Est. Completion 2019-12-01
Phase NA

Sponsor

Rush University Medical Center

320 total trials

What the Registry Record Tells You About NCT03590457

The ClinicalTrials.gov registry entry for NCT03590457 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Airvo 2; High-Flow nasal cannula system is the first listed.

NCT03590457 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03590457 about?

NCT03590457 is a clinical study titled "The Impact of High-Flow Nasal Cannula on Swallow Function". Background: High-flow nasal cannula (HFNC) is a non-invasive heated and humidified oxygen delivery device that is capable of delivering high-flow rates. It is a relatively new modality that has been introduced as an alternative to conventional oxygen therapy. The clinical value of the use of HFNC is...

What is the current status of trial NCT03590457?

This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2018-06-22. Estimated completion is 2019-12-01.

What interventions are being tested in trial NCT03590457?

The interventions under investigation include: Airvo 2; High-Flow nasal cannula system (DEVICE).

Who is sponsoring clinical trial NCT03590457?

This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.